Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Randomized, Double-Blind, Two-Way Crossover, Bioequivalence Study of SID530 and Taxotere® in Study Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Platinum Therapy Failure or Study Participants With Locally Advanced or Metastatic Breast Cancer Who Have Failed At Least One Prior Chemotherapeutic Regimen
This is a multi-center, randomized, blinded, two-period, two-sequence, crossover study, with
a minimum 3-week washout period between treatments.The study is designed to evaluate the
bioequivalence of SID530 to Taxotere.
It will be conducted in study participants with locally advanced or metastatic NSCLC who
have failed platinum therapy and also in participants with locally advanced or metastatic
breast cancer who have failed at least one line of chemotherapy.
Eligible study participants must be planning to have at least two consecutive 21-day cycles
with 75 mg/m2 docetaxel monotherapy.
The duration of study participation will be approximately 7 weeks. The study has three study
phases: Screening (<=1 week), Cycle 1 (21 days), and Cycle 2 (21 days).
Study participants who meet eligibility criteria will be randomized to one of two treatment
sequences (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1
followed by SID530 on Day 21). Randomization will be stratified by whether the study
participant received prior docetaxel treatment.
All study participants will be premedicated with oral dexamethasone, 16 mg per day (e.g. 8
mg b.i.d.) for three days, starting one day prior to each study drug infusion, in order to
reduce the incidence and severity of fluid retention as well as the severity of
hypersensitivity reactions. During each treatment cycle, both the test and the reference
treatments will receive identical dosages of docetaxel (i.e., 75 mg/m2, by i.v. infusion,
over 1 hour).
Study completion will be defined as completing all protocol-specified procedures. Study
participants who are prematurely withdrawn from the study will be requested to complete the
assessments conducted at the Final Visit.
Blood samples for pharmacokinetic analysis will be obtained at the predefined times during
Cycle 1 and Cycle 2.
Adverse events will be assessed throughout the study, including 21 days after the last study
drug infusion. Hematology assessments,other laboratory parameters and vital signs will be
assessed.
;
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |